Overview
Adam Swank is an associate in the Securities and Capital Markets practice and is based in the firm’s Century City office. His practice focuses on the representation of clients across the life sciences and technology industries, which include public and private companies as well as global investment banks. Adam advises clients in a variety of capital markets transactions including initial public offerings, follow-on offerings, at-the-market transactions and private placements of equity and debt securities. He also counsels clients with their corporate governance, securities law compliance and periodic reporting requirements.
Adam received his law degree from UCLA School of Law in 2023 where he served as the chief managing editor of the UCLA Journal of Law and Technology. While in law school, Adam was a writing advisor and was inducted into the Moot Court Honors Program. He earned a Bachelor of Arts degree in Broadcast Journalism, cum laude, from Texas State University where he managed the university’s radio station.
Adam is admitted to practice law in California.
news
- Paul Hastings Advised TD Cowen, Cantor, Stifel and RBC Capital Markets on Compass Pathways’ Underwritten Offering - January 10th, 2025
- Paul Hastings Advised J.P. Morgan and the Other Initial Purchasers in Blackstone Mortgage Trust, Inc.’s $450 Million Senior Secured Notes Offering - December 10th, 2024
- Paul Hastings Advised J.P. Morgan as Sole Book-Running Manager in Secondary Offering by Certain Stockholders of Harmony Biosciences - October 31st, 2024
- Paul Hastings Advised J.P. Morgan, Leerink Partners, Piper Sandler, and William Blair on CAMP4’s IPO - October 14th, 2024
- Paul Hastings Advised Varonis Systems on its Convertible Bond Offering - September 6th, 2024
- Paul Hastings Advised Stifel as Book-Running Manager on Precigen’s Common Stock Offering - August 9th, 2024
- Paul Hastings Advised Jefferies and Cantor as Joint Book-Running Managers in Rezolute’s Pricing of Common Stock and Pre-Funded Warrants Offering - June 14th, 2024
- Paul Hastings Advised Jefferies, J.P. Morgan, and Guggenheim Securities as Joint Book-Running Managers in Pricing of ProKidney’s Upsized Public Offering and Registered Direct Offering - June 12th, 2024
- Paul Hastings Advised TD Cowen and Wedbush PacGrow in Connection with Monte Rosa Therapeutics’ Underwritten Public Offering - May 16th, 2024
- Paul Hastings Advised Leerink Partners and Stifel in connection with Evolus Inc.’s Underwritten Offering - March 12th, 2024
- Paul Hastings Advised Underwriters on Humacyte’s $40 Million Public Offering - March 1st, 2024
- Paul Hastings Advised Leerink Partners on PepGen’s $80.1 Million Underwritten Offering - February 7th, 2024
- Paul Hastings Advised Jefferies LLC on Esperion Therapeutics’ $85.1 Million Public Offering - January 19th, 2024